Halozyme Therapeutics, Inc. (HALO) 10-Year Financial Performance & Capital Metrics

HALO • • Industrial / General

HealthcareBiotechnologyPlatform & Technology CompaniesAntibody Discovery Platforms

AboutHalozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.Show more

Revenue $1.02B +22.4%
EBITDA $633M +49.8%
Net Income $444M +57.7%
EPS (Diluted) 3.43 +63.3%
Gross Margin 84.3% +9.8%
EBITDA Margin 62.32% +22.3%
Operating Margin 54.32% +33.4%
Net Margin 43.74% +28.8%
ROE 198.42% -10.7%
ROIC 25.7% +47.5%
Debt/Equity 4.14 -76.9%
Interest Coverage 30.48 +69.4%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Excellent 3Y average ROE of 176.9%
✓Strong Piotroski F-Score: 9/9
✓FCF machine: 46.1% free cash flow margin
✓Strong 5Y sales CAGR of 39.0%
✓Share count reduced 3.6% through buybacks
✓Healthy 5Y average net margin of 49.5%

✗Weaknesses

✗High debt to equity ratio of 4.1x
✗Expensive at 25.5x book value

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y29.71%

5Y38.95%

3Y31.82%

TTM31.19%

Profit (Net Income) CAGR

10Y-

5Y-

3Y3.31%

TTM51.73%

EPS CAGR

10Y-

5Y-

3Y7.77%

TTM57.28%

ROCE

10Y Avg8.17%

5Y Avg32.91%

3Y Avg23.74%

Latest31.11%

Peer Comparison

Antibody Discovery Platforms

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
NAGENiagen Bioscience Inc	503.58M	6.31	57.36	19.18%	16.38%	28.91%	2.37%	0.06
BTXBlackRock Technology and Private Equity Term Trust	808.8M	6.93	40.76	-81.13%	87.75%	1.87%	34.27%
HALOHalozyme Therapeutics, Inc.	8.45B	71.82	20.94	22.44%	47.91%	118.17%	5.55%	4.14
RPRXRoyalty Pharma plc	16.97B	39.72	20.80	-3.86%	32.55%	7.95%	16.32%	0.74
REGNRegeneron Pharmaceuticals, Inc.	76.63B	741.92	19.35	8.27%	32.13%	14.79%	4.78%	0.09
GMABGenmab A/S	20.85B	33.85	2.79	30.67%	46.8%	114.25%	36.37%	0.03
DNAGinkgo Bioworks Holdings, Inc.	464.86M	9.58	-0.91	-9.71%	-188%	-60.66%		0.65
PRMEPrime Medicine, Inc.	720.24M	3.99	-2.42		-33.02%	-121.95%		0.27

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	135.06M	146.69M	316.61M	151.86M	195.99M	267.59M	443.31M	660.12M	829.25M	1.02B
Revenue Growth %	0.79%	0.09%	1.16%	-0.52%	0.29%	0.37%	0.66%	0.49%	0.26%	0.22%
Cost of Goods Sold+	29.25M	33.21M	31.15M	10.14M	45.55M	43.37M	81.41M	139.3M	192.36M	159.42M
COGS % of Revenue	0.22%	0.23%	0.1%	0.07%	0.23%	0.16%	0.18%	0.21%	0.23%	0.16%
Gross Profit+	105.81M	113.48M	285.46M	141.73M	150.45M	224.23M	361.9M	520.81M	636.89M	855.91M
Gross Margin %	0.78%	0.77%	0.9%	0.93%	0.77%	0.84%	0.82%	0.79%	0.77%	0.84%
Gross Profit Growth %	1.01%	0.07%	1.52%	-0.5%	0.06%	0.49%	0.61%	0.44%	0.22%	0.34%
Operating Expenses+	133.26M	196.69M	204.46M	211.06M	218.06M	79.97M	86M	253.28M	299.32M	304.43M
OpEx % of Revenue	0.99%	1.34%	0.65%	1.39%	1.11%	0.3%	0.19%	0.38%	0.36%	0.3%
Selling, General & Admin	40.03M	45.85M	53.82M	60.8M	77.25M	45.74M	50.32M	143.53M	149.18M	154.34M
SG&A % of Revenue	0.3%	0.31%	0.17%	0.4%	0.39%	0.17%	0.11%	0.22%	0.18%	0.15%
Research & Development	93.24M	150.84M	150.64M	150.25M	140.8M	34.24M	35.67M	66.61M	76.36M	79.05M
R&D % of Revenue	0.69%	1.03%	0.48%	0.99%	0.72%	0.13%	0.08%	0.1%	0.09%	0.08%
Other Operating Expenses	0	0	0	0	0	0	0	43.15M	73.77M	71.05M
Operating Income+	-27.45M	-83.21M	81M	-69.33M	-67.61M	144.25M	275.9M	267.53M	337.57M	551.48M
Operating Margin %	-0.2%	-0.57%	0.26%	-0.46%	-0.34%	0.54%	0.62%	0.41%	0.41%	0.54%
Operating Income Growth %	0.56%	-2.03%	1.97%	-1.86%	0.02%	3.13%	0.91%	-0.03%	0.26%	0.63%
EBITDA+	-25.77M	-80.8M	83.16M	-66.94M	-63.54M	147.54M	278.9M	317.17M	422.43M	632.79M
EBITDA Margin %	-0.19%	-0.55%	0.26%	-0.44%	-0.32%	0.55%	0.63%	0.48%	0.51%	0.62%
EBITDA Growth %	0.58%	-2.13%	2.03%	-1.8%	0.05%	3.32%	0.89%	0.14%	0.33%	0.5%
D&A (Non-Cash Add-back)	1.68M	2.41M	2.16M	2.39M	4.07M	3.28M	3M	49.64M	84.86M	81.31M
EBIT	-27.03M	-81.88M	81M	-69.33M	-60.62M	149.68M	256.04M	265.87M	367.09M	575.23M
Net Interest Income+	-5.2M	-19.98M	-21.98M	-18.04M	-11.63M	-20.38M	-7.53M	-16.95M	-18.76M	-18.09M
Interest Income	0	0	0	0	0	0	0	0	0	0
Interest Expense	5.2M	19.98M	21.98M	18.04M	11.63M	20.38M	7.53M	16.95M	18.76M	18.09M
Other Income/Expense	-4.78M	-18.65M	-19.39M	-10.46M	-4.64M	-14.95M	-27.38M	-18.61M	10.76M	5.66M
Pretax Income+	-32.23M	-101.86M	61.61M	-79.79M	-72.25M	129.3M	248.52M	248.92M	348.33M	557.13M
Pretax Margin %	-0.24%	-0.69%	0.19%	-0.53%	-0.37%	0.48%	0.56%	0.38%	0.42%	0.55%
Income Tax+	0	1.16M	-1.36M	537K	-11K	217K	-154.19M	46.79M	66.73M	113.04M
Effective Tax Rate %	1%	1.01%	1.02%	1.01%	1%	1%	1.62%	0.81%	0.81%	0.8%
Net Income+	-32.23M	-103.02M	62.97M	-80.33M	-72.24M	129.09M	402.71M	202.13M	281.59M	444.09M
Net Margin %	-0.24%	-0.7%	0.2%	-0.53%	-0.37%	0.48%	0.91%	0.31%	0.34%	0.44%
Net Income Growth %	0.53%	-2.2%	1.61%	-2.28%	0.1%	2.79%	2.12%	-0.5%	0.39%	0.58%
Net Income (Continuing)	-32.23M	-103.02M	62.97M	-80.33M	-72.24M	129.09M	402.71M	202.13M	281.59M	444.09M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.25	-0.81	0.45	-0.56	-0.50	0.91	2.74	1.44	2.10	3.43
EPS Growth %	0.55%	-2.24%	1.56%	-2.24%	0.11%	2.82%	2.01%	-0.47%	0.46%	0.63%
EPS (Basic)	-0.25	-0.81	0.46	-0.56	-0.50	0.95	2.86	1.48	2.13	3.50
Diluted Shares Outstanding	126.7M	127.96M	139.07M	143.6M	144.33M	141.46M	146.8M	140.61M	134.2M	129.42M
Basic Shares Outstanding	126.7M	127.19M	136.42M	143.45M	144.33M	136.21M	140.65M	136.84M	131.93M	126.83M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	171.77M	256.53M	510.37M	427.85M	543.44M	554.76M	926.29M	739.01M	746.42M	1.09B
Cash & Short-Term Investments	108.34M	204.98M	469.21M	354.53M	421.26M	368.01M	740.92M	362.79M	336M	596.07M
Cash Only	43.29M	66.76M	168.74M	57.94M	120.18M	147.7M	118.72M	234.19M	118.37M	115.85M
Short-Term Investments	65.05M	138.22M	300.47M	296.59M	301.08M	220.31M	622.2M	128.6M	217.63M	480.22M
Accounts Receivable	32.41M	15.68M	22.13M	30M	59.44M	97.73M	90.97M	231.07M	234.21M	308.45M
Days Sales Outstanding	87.59	39.02	25.52	72.12	110.7	133.3	74.9	127.77	103.09	110.89
Inventory	9.49M	14.62M	5.15M	22.63M	29.36M	60.75M	53.91M	100.12M	127.6M	141.86M
Days Inventory Outstanding	118.43	160.74	60.29	814.73	235.28	511.28	241.69	262.34	242.12	324.8
Other Current Assets	0	0	0	0	0	0	0	45.02M	48.61M	38.95M
Total Non-Current Assets+	10.02M	4.98M	9.57M	12.4M	22.44M	25.16M	178.14M	1.1B	986.85M	978.14M
Property, Plant & Equipment	3.94M	4.26M	3.52M	7.46M	10.86M	10.59M	8.79M	75.57M	74.94M	75.03M
Fixed Asset Turnover	34.25x	34.40x	89.95x	20.34x	18.06x	25.26x	50.41x	8.74x	11.06x	13.53x
Goodwill	0	0	0	0	0	0	0	409.05M	416.82M	416.82M
Intangible Assets	0	0	0	0	0	0	0	546.65M	472.88M	401.83M
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	6.07M	719K	6.05M	4.93M	11.58M	14.57M	13.91M	26.8M	17.82M	80.6M
Total Assets+	181.79M	261.51M	519.95M	440.25M	565.87M	579.92M	1.1B	1.84B	1.73B	2.06B
Asset Turnover	0.74x	0.56x	0.61x	0.34x	0.35x	0.46x	0.40x	0.36x	0.48x	0.49x
Asset Growth %	0.1%	0.44%	0.99%	-0.15%	0.29%	0.02%	0.9%	0.67%	-0.06%	0.19%
Total Current Liabilities+	62.46M	54.59M	131.33M	149.36M	85.64M	421.38M	117.15M	130.79M	112.49M	139.1M
Accounts Payable	4.5M	3.58M	7.95M	4.08M	6.43M	1.93M	1.54M	17.69M	11.82M	10.25M
Days Payables Outstanding	56.15	39.33	93.12	146.89	51.56	16.23	6.91	46.36	22.42	23.47
Short-Term Debt	21.86M	17.39M	77.21M	91.51M	19.54M	397.23M	89.42M	13.33M	0	0
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	0	0
Other Current Liabilities	0	0	0	0	0	0	0	-3.25M	0	0
Current Ratio	2.75x	4.70x	3.89x	2.86x	6.35x	1.32x	7.91x	5.65x	6.64x	7.80x
Quick Ratio	2.60x	4.43x	3.85x	2.71x	6.00x	1.17x	7.45x	4.88x	5.50x	6.78x
Cash Conversion Cycle	149.87	160.42	-7.31	739.96	294.42	628.36	309.68	343.75	322.79	412.22
Total Non-Current Liabilities+	76.33M	239.41M	180.25M	42M	388.47M	7.49M	790.33M	1.54B	1.54B	1.56B
Long-Term Debt	27.97M	199.23M	125.14M	34.87M	383.05M	0	787.25M	1.49B	1.5B	1.51B
Capital Lease Obligations	0	0	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	4.44M	358K	814K	2.12M	4.18M	3.47M	544K	45.91M	37.72M	54.76M
Total Liabilities	138.79M	294M	311.58M	191.36M	474.11M	428.88M	907.48M	1.67B	1.65B	1.7B
Total Debt+	49.83M	216.62M	202.35M	126.38M	402.59M	397.23M	876.67M	1.51B	1.5B	1.51B
Net Debt	6.54M	149.86M	33.61M	68.44M	282.41M	249.53M	757.96M	1.27B	1.38B	1.39B
Debt / Equity	1.16x	-	0.97x	0.51x	4.39x	2.63x	4.45x	8.87x	17.89x	4.14x
Debt / EBITDA	-	-	2.43x	-	-	2.69x	3.14x	4.75x	3.55x	2.38x
Net Debt / EBITDA	-	-	0.40x	-	-	1.69x	2.72x	4.01x	3.27x	2.20x
Interest Coverage	-5.28x	-4.17x	3.68x	-3.84x	-5.81x	7.08x	36.66x	15.79x	17.99x	30.48x
Total Equity+	43M	-32.48M	208.37M	248.89M	91.77M	151.05M	196.95M	169.8M	83.81M	363.82M
Equity Growth %	0.04%	-1.76%	7.42%	0.19%	-0.63%	0.65%	0.3%	-0.14%	-0.51%	3.34%
Book Value per Share	0.34	-0.25	1.50	1.73	0.64	1.07	1.34	1.21	0.62	2.81
Total Shareholders' Equity	43M	-32.48M	208.37M	248.89M	91.77M	151.05M	196.95M	169.8M	83.81M	363.82M
Common Stock	128K	130K	143K	145K	137K	135K	138K	135K	127K	123K
Retained Earnings	-482.66M	-585.34M	-522.37M	-531.44M	-603.68M	-474.59M	-58.91M	143.22M	90.55M	359.87M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-99K	-6K	-450K	-277K	240K	22K	-620K	-922K	-9.28M	3.83M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-37.08M	-50.38M	134.05M	-49.5M	-85.42M	55.45M	299.44M	240.11M	388.57M	479.06M
Operating CF Margin %	-0.27%	-0.34%	0.42%	-0.33%	-0.44%	0.21%	0.68%	0.36%	0.47%	0.47%
Operating CF Growth %	0.22%	-0.36%	3.66%	-1.37%	-0.73%	1.65%	4.4%	-0.2%	0.62%	0.23%
Net Income	-32.23M	-103.02M	62.97M	-80.33M	-72.24M	129.09M	402.71M	202.13M	281.59M	444.09M
Depreciation & Amortization	1.68M	2.41M	2.16M	2.39M	6.55M	17.42M	6.64M	57.48M	84.86M	88.66M
Stock-Based Compensation	20.84M	25.59M	30.67M	35.7M	34.78M	17.2M	20.82M	24.4M	36.62M	43.38M
Deferred Taxes	887K	560K	-257K	-3.08M	0	0	0	0	34.51M	0
Other Non-Cash Items	1.24M	7.11M	17.82M	1.7M	666K	-41.1M	-133.3M	66.59M	-10.33M	39.2M
Working Capital Changes	-29.5M	16.98M	20.69M	-5.87M	-55.18M	-67.16M	2.57M	-110.49M	-38.67M	-136.27M
Change in Receivables	-23.26M	16.73M	-6.45M	11.61M	-29.44M	-38.29M	6.75M	-83.94M	-3.34M	-74.25M
Change in Inventory	-3.08M	-5.13M	9.48M	-17.48M	-6.73M	-31.39M	7.37M	-17.48M	-26.88M	-67.38M
Change in Payables	13.87M	-244K	15.63M	-278.49M	0	0	0	0	-12.55M	0
Cash from Investing+	5.89M	-76.77M	-163.73M	2.49M	-5.55M	78.35M	-406.29M	-487M	-96.91M	-262.72M
Capital Expenditures	-2.36M	-3.14M	-1.35M	-4.66M	-4.04M	-2.5M	-1.46M	-4.81M	-15.29M	-10.7M
CapEx % of Revenue	0.02%	0.02%	0%	0.03%	0.02%	0.01%	0%	0.01%	0.02%	0.01%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	8.25M	-73.63M	-162.38M	7.16M	-1.51M	80.86M	-404.83M	516.92M	0	-252.03M
Cash from Financing+	13.1M	150.62M	131.66M	-63.8M	153.22M	-106.28M	77.86M	362.37M	-407.99M	-218.86M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	13.1M	1.86M	12.78M	13.72M	13.95M	63.39M	12.11M	-62.17M	7.88M	31.14M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-39.44M	-53.52M	132.7M	-54.16M	-89.46M	52.95M	297.98M	235.3M	373.28M	468.37M
FCF Margin %	-0.29%	-0.36%	0.42%	-0.36%	-0.46%	0.2%	0.67%	0.36%	0.45%	0.46%
FCF Growth %	0.19%	-0.36%	3.48%	-1.41%	-0.65%	1.59%	4.63%	-0.21%	0.59%	0.25%
FCF per Share	-0.31	-0.42	0.95	-0.38	-0.62	0.37	2.03	1.67	2.78	3.62
FCF Conversion (FCF/Net Income)	1.15x	0.49x	2.13x	0.62x	1.18x	0.43x	0.74x	1.19x	1.38x	1.08x
Interest Paid	0	3.89M	20.3M	16.89M	9.03M	6.53M	3.3M	6.11M	11.41M	10.56M
Taxes Paid	0	1.44M	3.02M	220K	0	0	0	0	31.76M	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-76.42%	-1958.98%	71.6%	-35.14%	-42.41%	106.33%	231.44%	110.23%	222.07%	198.42%
Return on Invested Capital (ROIC)	-51.89%	-74.78%	33.81%	-18.59%	-14.67%	27.93%	30.53%	16.74%	17.42%	25.7%
Gross Margin	78.35%	77.36%	90.16%	93.33%	76.76%	83.79%	81.64%	78.9%	76.8%	84.3%
Net Margin	-23.86%	-70.23%	19.89%	-52.9%	-36.86%	48.24%	90.84%	30.62%	33.96%	43.74%
Debt / Equity	1.16x	-	0.97x	0.51x	4.39x	2.63x	4.45x	8.87x	17.89x	4.14x
Interest Coverage	-5.28x	-4.17x	3.68x	-3.84x	-5.81x	7.08x	36.66x	15.79x	17.99x	30.48x
FCF Conversion	1.15x	0.49x	2.13x	0.62x	1.18x	0.43x	0.74x	1.19x	1.38x	1.08x
Revenue Growth	79.28%	8.61%	115.84%	-52.04%	29.06%	36.53%	65.67%	48.91%	25.62%	22.44%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Royalty	-	-	-	-	69.9M	88.6M	203.9M	360.48M	447.87M	570.99M
Royalty Growth	-	-	-	-	-	26.75%	130.15%	76.79%	24.24%	27.49%
Product	-	-	-	-	66.05M	55.99M	104.22M	191.03M	300.85M	303.49M
Product Growth	-	-	-	-	-	-15.23%	86.16%	83.29%	57.49%	0.88%
Collaborative Agreements	-	-	-	-	60.05M	123.01M	135.19M	108.61M	80.53M	140.84M
Collaborative Agreements Growth	-	-	-	-	-	104.86%	9.90%	-19.66%	-25.85%	74.88%
Bulk rHuPH20	-	-	-	-	-	-	-	-	115.44M	86.33M
Bulk rHuPH20 Growth	-	-	-	-	-	-	-	-	-	-25.21%
Sales-based milestone	-	-	-	-	-	15M	50M	10M	-	30M
Sales-based milestone Growth	-	-	-	-	-	-	233.33%	-80.00%	-	-
Upfront Fees	-	-	-	-	-	-	-	-	-	27M
Upfront Fees Growth	-	-	-	-	-	-	-	-	-	-
Research and Development Services	-	-	-	-	1.54M	1.25M	1.19M	9.61M	9.53M	-
Research and Development Services Growth	-	-	-	-	-	-19.29%	-4.89%	710.37%	-0.80%	-
Upfront fees	-	-	-	-	53M	37.26M	42M	30M	2M	-
Upfront fees Growth	-	-	-	-	-	-29.69%	12.71%	-28.57%	-93.33%	-
bulk rHuPH20	-	-	-	12.73M	48.28M	38.24M	80.96M	82.08M	-	-
bulk rHuPH20 Growth	-	-	-	-	279.33%	-20.81%	111.73%	1.39%	-	-
Development Fees	-	-	-	-	5.5M	69.5M	42M	59M	-	-
Development Fees Growth	-	-	-	-	-	1163.64%	-39.57%	40.48%	-	-
Hylenex Recombinant	-	-	-	-	17M	17.03M	23.26M	-	-	-
Hylenex Recombinant Growth	-	-	-	-	-	0.21%	36.59%	-	-	-
ENHANZE drug product	-	-	-	-	768K	719K	-	-	-	-
ENHANZE drug product Growth	-	-	-	-	-	-6.38%	-	-	-	-
Bulk rHuPH20 for Herceptin SC	22.8M	-	-	-	-	-	-	-	-	-
Bulk rHuPH20 for Herceptin SC Growth	-	-	-	-	-	-	-	-	-	-
Bulk rHuPH20 for HyQvia	6.4M	-	-	-	-	-	-	-	-	-
Bulk rHuPH20 for HyQvia Growth	-	-	-	-	-	-	-	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
SWITZERLAND	57.14M	93.07M	119.14M	109.89M	-	-	-	-	-	-
SWITZERLAND Growth	-	62.89%	28.01%	-7.76%	-	-	-	-	-	-
UNITED STATES	77.15M	52.29M	196.27M	40.48M	-	-	-	-	-	-
UNITED STATES Growth	-	-32.22%	275.34%	-79.38%	-	-	-	-	-	-
Foreign Countries	772K	1.33M	-	-	-	-	-	-	-	-
Foreign Countries Growth	-	72.54%	-	-	-	-	-	-	-	-

Frequently Asked Questions

Valuation & Price

Halozyme Therapeutics, Inc. (HALO) has a price-to-earnings (P/E) ratio of 20.9x. This is roughly in line with market averages.

Growth & Financials

Halozyme Therapeutics, Inc. (HALO) reported $1.24B in revenue for fiscal year 2024. This represents a 2116% increase from $56.1M in 2011.

Halozyme Therapeutics, Inc. (HALO) grew revenue by 22.4% over the past year. This is strong growth.

Yes, Halozyme Therapeutics, Inc. (HALO) is profitable, generating $595.5M in net income for fiscal year 2024 (43.7% net margin).

Dividend & Returns

Halozyme Therapeutics, Inc. (HALO) has a return on equity (ROE) of 198.4%. This is excellent, indicating efficient use of shareholder capital.

Halozyme Therapeutics, Inc. (HALO) generated $602.4M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...

Halozyme Therapeutics, Inc. (HALO) 10-Year Financial Performance & Capital Metrics

HALO • • Industrial / General

HealthcareBiotechnologyPlatform & Technology CompaniesAntibody Discovery Platforms

Revenue $1.02B +22.4%
EBITDA $633M +49.8%
Net Income $444M +57.7%
EPS (Diluted) 3.43 +63.3%
Gross Margin 84.3% +9.8%
EBITDA Margin 62.32% +22.3%
Operating Margin 54.32% +33.4%
Net Margin 43.74% +28.8%
ROE 198.42% -10.7%
ROIC 25.7% +47.5%
Debt/Equity 4.14 -76.9%
Interest Coverage 30.48 +69.4%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Excellent 3Y average ROE of 176.9%
✓Strong Piotroski F-Score: 9/9
✓FCF machine: 46.1% free cash flow margin
✓Strong 5Y sales CAGR of 39.0%
✓Share count reduced 3.6% through buybacks
✓Healthy 5Y average net margin of 49.5%

✗Weaknesses

✗High debt to equity ratio of 4.1x
✗Expensive at 25.5x book value

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y29.71%

5Y38.95%

3Y31.82%

TTM31.19%

Profit (Net Income) CAGR

10Y-

5Y-

3Y3.31%

TTM51.73%

EPS CAGR

10Y-

5Y-

3Y7.77%

TTM57.28%

ROCE

10Y Avg8.17%

5Y Avg32.91%

3Y Avg23.74%

Latest31.11%

Peer Comparison

Antibody Discovery Platforms

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
NAGENiagen Bioscience Inc	503.58M	6.31	57.36	19.18%	16.38%	28.91%	2.37%	0.06
BTXBlackRock Technology and Private Equity Term Trust	808.8M	6.93	40.76	-81.13%	87.75%	1.87%	34.27%
HALOHalozyme Therapeutics, Inc.	8.45B	71.82	20.94	22.44%	47.91%	118.17%	5.55%	4.14
RPRXRoyalty Pharma plc	16.97B	39.72	20.80	-3.86%	32.55%	7.95%	16.32%	0.74
REGNRegeneron Pharmaceuticals, Inc.	76.63B	741.92	19.35	8.27%	32.13%	14.79%	4.78%	0.09
GMABGenmab A/S	20.85B	33.85	2.79	30.67%	46.8%	114.25%	36.37%	0.03
DNAGinkgo Bioworks Holdings, Inc.	464.86M	9.58	-0.91	-9.71%	-188%	-60.66%		0.65
PRMEPrime Medicine, Inc.	720.24M	3.99	-2.42		-33.02%	-121.95%		0.27

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	135.06M	146.69M	316.61M	151.86M	195.99M	267.59M	443.31M	660.12M	829.25M	1.02B
Revenue Growth %	0.79%	0.09%	1.16%	-0.52%	0.29%	0.37%	0.66%	0.49%	0.26%	0.22%
Cost of Goods Sold+	29.25M	33.21M	31.15M	10.14M	45.55M	43.37M	81.41M	139.3M	192.36M	159.42M
COGS % of Revenue	0.22%	0.23%	0.1%	0.07%	0.23%	0.16%	0.18%	0.21%	0.23%	0.16%
Gross Profit+	105.81M	113.48M	285.46M	141.73M	150.45M	224.23M	361.9M	520.81M	636.89M	855.91M
Gross Margin %	0.78%	0.77%	0.9%	0.93%	0.77%	0.84%	0.82%	0.79%	0.77%	0.84%
Gross Profit Growth %	1.01%	0.07%	1.52%	-0.5%	0.06%	0.49%	0.61%	0.44%	0.22%	0.34%
Operating Expenses+	133.26M	196.69M	204.46M	211.06M	218.06M	79.97M	86M	253.28M	299.32M	304.43M
OpEx % of Revenue	0.99%	1.34%	0.65%	1.39%	1.11%	0.3%	0.19%	0.38%	0.36%	0.3%
Selling, General & Admin	40.03M	45.85M	53.82M	60.8M	77.25M	45.74M	50.32M	143.53M	149.18M	154.34M
SG&A % of Revenue	0.3%	0.31%	0.17%	0.4%	0.39%	0.17%	0.11%	0.22%	0.18%	0.15%
Research & Development	93.24M	150.84M	150.64M	150.25M	140.8M	34.24M	35.67M	66.61M	76.36M	79.05M
R&D % of Revenue	0.69%	1.03%	0.48%	0.99%	0.72%	0.13%	0.08%	0.1%	0.09%	0.08%
Other Operating Expenses	0	0	0	0	0	0	0	43.15M	73.77M	71.05M
Operating Income+	-27.45M	-83.21M	81M	-69.33M	-67.61M	144.25M	275.9M	267.53M	337.57M	551.48M
Operating Margin %	-0.2%	-0.57%	0.26%	-0.46%	-0.34%	0.54%	0.62%	0.41%	0.41%	0.54%
Operating Income Growth %	0.56%	-2.03%	1.97%	-1.86%	0.02%	3.13%	0.91%	-0.03%	0.26%	0.63%
EBITDA+	-25.77M	-80.8M	83.16M	-66.94M	-63.54M	147.54M	278.9M	317.17M	422.43M	632.79M
EBITDA Margin %	-0.19%	-0.55%	0.26%	-0.44%	-0.32%	0.55%	0.63%	0.48%	0.51%	0.62%
EBITDA Growth %	0.58%	-2.13%	2.03%	-1.8%	0.05%	3.32%	0.89%	0.14%	0.33%	0.5%
D&A (Non-Cash Add-back)	1.68M	2.41M	2.16M	2.39M	4.07M	3.28M	3M	49.64M	84.86M	81.31M
EBIT	-27.03M	-81.88M	81M	-69.33M	-60.62M	149.68M	256.04M	265.87M	367.09M	575.23M
Net Interest Income+	-5.2M	-19.98M	-21.98M	-18.04M	-11.63M	-20.38M	-7.53M	-16.95M	-18.76M	-18.09M
Interest Income	0	0	0	0	0	0	0	0	0	0
Interest Expense	5.2M	19.98M	21.98M	18.04M	11.63M	20.38M	7.53M	16.95M	18.76M	18.09M
Other Income/Expense	-4.78M	-18.65M	-19.39M	-10.46M	-4.64M	-14.95M	-27.38M	-18.61M	10.76M	5.66M
Pretax Income+	-32.23M	-101.86M	61.61M	-79.79M	-72.25M	129.3M	248.52M	248.92M	348.33M	557.13M
Pretax Margin %	-0.24%	-0.69%	0.19%	-0.53%	-0.37%	0.48%	0.56%	0.38%	0.42%	0.55%
Income Tax+	0	1.16M	-1.36M	537K	-11K	217K	-154.19M	46.79M	66.73M	113.04M
Effective Tax Rate %	1%	1.01%	1.02%	1.01%	1%	1%	1.62%	0.81%	0.81%	0.8%
Net Income+	-32.23M	-103.02M	62.97M	-80.33M	-72.24M	129.09M	402.71M	202.13M	281.59M	444.09M
Net Margin %	-0.24%	-0.7%	0.2%	-0.53%	-0.37%	0.48%	0.91%	0.31%	0.34%	0.44%
Net Income Growth %	0.53%	-2.2%	1.61%	-2.28%	0.1%	2.79%	2.12%	-0.5%	0.39%	0.58%
Net Income (Continuing)	-32.23M	-103.02M	62.97M	-80.33M	-72.24M	129.09M	402.71M	202.13M	281.59M	444.09M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.25	-0.81	0.45	-0.56	-0.50	0.91	2.74	1.44	2.10	3.43
EPS Growth %	0.55%	-2.24%	1.56%	-2.24%	0.11%	2.82%	2.01%	-0.47%	0.46%	0.63%
EPS (Basic)	-0.25	-0.81	0.46	-0.56	-0.50	0.95	2.86	1.48	2.13	3.50
Diluted Shares Outstanding	126.7M	127.96M	139.07M	143.6M	144.33M	141.46M	146.8M	140.61M	134.2M	129.42M
Basic Shares Outstanding	126.7M	127.19M	136.42M	143.45M	144.33M	136.21M	140.65M	136.84M	131.93M	126.83M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	171.77M	256.53M	510.37M	427.85M	543.44M	554.76M	926.29M	739.01M	746.42M	1.09B
Cash & Short-Term Investments	108.34M	204.98M	469.21M	354.53M	421.26M	368.01M	740.92M	362.79M	336M	596.07M
Cash Only	43.29M	66.76M	168.74M	57.94M	120.18M	147.7M	118.72M	234.19M	118.37M	115.85M
Short-Term Investments	65.05M	138.22M	300.47M	296.59M	301.08M	220.31M	622.2M	128.6M	217.63M	480.22M
Accounts Receivable	32.41M	15.68M	22.13M	30M	59.44M	97.73M	90.97M	231.07M	234.21M	308.45M
Days Sales Outstanding	87.59	39.02	25.52	72.12	110.7	133.3	74.9	127.77	103.09	110.89
Inventory	9.49M	14.62M	5.15M	22.63M	29.36M	60.75M	53.91M	100.12M	127.6M	141.86M
Days Inventory Outstanding	118.43	160.74	60.29	814.73	235.28	511.28	241.69	262.34	242.12	324.8
Other Current Assets	0	0	0	0	0	0	0	45.02M	48.61M	38.95M
Total Non-Current Assets+	10.02M	4.98M	9.57M	12.4M	22.44M	25.16M	178.14M	1.1B	986.85M	978.14M
Property, Plant & Equipment	3.94M	4.26M	3.52M	7.46M	10.86M	10.59M	8.79M	75.57M	74.94M	75.03M
Fixed Asset Turnover	34.25x	34.40x	89.95x	20.34x	18.06x	25.26x	50.41x	8.74x	11.06x	13.53x
Goodwill	0	0	0	0	0	0	0	409.05M	416.82M	416.82M
Intangible Assets	0	0	0	0	0	0	0	546.65M	472.88M	401.83M
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	6.07M	719K	6.05M	4.93M	11.58M	14.57M	13.91M	26.8M	17.82M	80.6M
Total Assets+	181.79M	261.51M	519.95M	440.25M	565.87M	579.92M	1.1B	1.84B	1.73B	2.06B
Asset Turnover	0.74x	0.56x	0.61x	0.34x	0.35x	0.46x	0.40x	0.36x	0.48x	0.49x
Asset Growth %	0.1%	0.44%	0.99%	-0.15%	0.29%	0.02%	0.9%	0.67%	-0.06%	0.19%
Total Current Liabilities+	62.46M	54.59M	131.33M	149.36M	85.64M	421.38M	117.15M	130.79M	112.49M	139.1M
Accounts Payable	4.5M	3.58M	7.95M	4.08M	6.43M	1.93M	1.54M	17.69M	11.82M	10.25M
Days Payables Outstanding	56.15	39.33	93.12	146.89	51.56	16.23	6.91	46.36	22.42	23.47
Short-Term Debt	21.86M	17.39M	77.21M	91.51M	19.54M	397.23M	89.42M	13.33M	0	0
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	0	0
Other Current Liabilities	0	0	0	0	0	0	0	-3.25M	0	0
Current Ratio	2.75x	4.70x	3.89x	2.86x	6.35x	1.32x	7.91x	5.65x	6.64x	7.80x
Quick Ratio	2.60x	4.43x	3.85x	2.71x	6.00x	1.17x	7.45x	4.88x	5.50x	6.78x
Cash Conversion Cycle	149.87	160.42	-7.31	739.96	294.42	628.36	309.68	343.75	322.79	412.22
Total Non-Current Liabilities+	76.33M	239.41M	180.25M	42M	388.47M	7.49M	790.33M	1.54B	1.54B	1.56B
Long-Term Debt	27.97M	199.23M	125.14M	34.87M	383.05M	0	787.25M	1.49B	1.5B	1.51B
Capital Lease Obligations	0	0	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	4.44M	358K	814K	2.12M	4.18M	3.47M	544K	45.91M	37.72M	54.76M
Total Liabilities	138.79M	294M	311.58M	191.36M	474.11M	428.88M	907.48M	1.67B	1.65B	1.7B
Total Debt+	49.83M	216.62M	202.35M	126.38M	402.59M	397.23M	876.67M	1.51B	1.5B	1.51B
Net Debt	6.54M	149.86M	33.61M	68.44M	282.41M	249.53M	757.96M	1.27B	1.38B	1.39B
Debt / Equity	1.16x	-	0.97x	0.51x	4.39x	2.63x	4.45x	8.87x	17.89x	4.14x
Debt / EBITDA	-	-	2.43x	-	-	2.69x	3.14x	4.75x	3.55x	2.38x
Net Debt / EBITDA	-	-	0.40x	-	-	1.69x	2.72x	4.01x	3.27x	2.20x
Interest Coverage	-5.28x	-4.17x	3.68x	-3.84x	-5.81x	7.08x	36.66x	15.79x	17.99x	30.48x
Total Equity+	43M	-32.48M	208.37M	248.89M	91.77M	151.05M	196.95M	169.8M	83.81M	363.82M
Equity Growth %	0.04%	-1.76%	7.42%	0.19%	-0.63%	0.65%	0.3%	-0.14%	-0.51%	3.34%
Book Value per Share	0.34	-0.25	1.50	1.73	0.64	1.07	1.34	1.21	0.62	2.81
Total Shareholders' Equity	43M	-32.48M	208.37M	248.89M	91.77M	151.05M	196.95M	169.8M	83.81M	363.82M
Common Stock	128K	130K	143K	145K	137K	135K	138K	135K	127K	123K
Retained Earnings	-482.66M	-585.34M	-522.37M	-531.44M	-603.68M	-474.59M	-58.91M	143.22M	90.55M	359.87M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-99K	-6K	-450K	-277K	240K	22K	-620K	-922K	-9.28M	3.83M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-37.08M	-50.38M	134.05M	-49.5M	-85.42M	55.45M	299.44M	240.11M	388.57M	479.06M
Operating CF Margin %	-0.27%	-0.34%	0.42%	-0.33%	-0.44%	0.21%	0.68%	0.36%	0.47%	0.47%
Operating CF Growth %	0.22%	-0.36%	3.66%	-1.37%	-0.73%	1.65%	4.4%	-0.2%	0.62%	0.23%
Net Income	-32.23M	-103.02M	62.97M	-80.33M	-72.24M	129.09M	402.71M	202.13M	281.59M	444.09M
Depreciation & Amortization	1.68M	2.41M	2.16M	2.39M	6.55M	17.42M	6.64M	57.48M	84.86M	88.66M
Stock-Based Compensation	20.84M	25.59M	30.67M	35.7M	34.78M	17.2M	20.82M	24.4M	36.62M	43.38M
Deferred Taxes	887K	560K	-257K	-3.08M	0	0	0	0	34.51M	0
Other Non-Cash Items	1.24M	7.11M	17.82M	1.7M	666K	-41.1M	-133.3M	66.59M	-10.33M	39.2M
Working Capital Changes	-29.5M	16.98M	20.69M	-5.87M	-55.18M	-67.16M	2.57M	-110.49M	-38.67M	-136.27M
Change in Receivables	-23.26M	16.73M	-6.45M	11.61M	-29.44M	-38.29M	6.75M	-83.94M	-3.34M	-74.25M
Change in Inventory	-3.08M	-5.13M	9.48M	-17.48M	-6.73M	-31.39M	7.37M	-17.48M	-26.88M	-67.38M
Change in Payables	13.87M	-244K	15.63M	-278.49M	0	0	0	0	-12.55M	0
Cash from Investing+	5.89M	-76.77M	-163.73M	2.49M	-5.55M	78.35M	-406.29M	-487M	-96.91M	-262.72M
Capital Expenditures	-2.36M	-3.14M	-1.35M	-4.66M	-4.04M	-2.5M	-1.46M	-4.81M	-15.29M	-10.7M
CapEx % of Revenue	0.02%	0.02%	0%	0.03%	0.02%	0.01%	0%	0.01%	0.02%	0.01%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	8.25M	-73.63M	-162.38M	7.16M	-1.51M	80.86M	-404.83M	516.92M	0	-252.03M
Cash from Financing+	13.1M	150.62M	131.66M	-63.8M	153.22M	-106.28M	77.86M	362.37M	-407.99M	-218.86M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	13.1M	1.86M	12.78M	13.72M	13.95M	63.39M	12.11M	-62.17M	7.88M	31.14M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-39.44M	-53.52M	132.7M	-54.16M	-89.46M	52.95M	297.98M	235.3M	373.28M	468.37M
FCF Margin %	-0.29%	-0.36%	0.42%	-0.36%	-0.46%	0.2%	0.67%	0.36%	0.45%	0.46%
FCF Growth %	0.19%	-0.36%	3.48%	-1.41%	-0.65%	1.59%	4.63%	-0.21%	0.59%	0.25%
FCF per Share	-0.31	-0.42	0.95	-0.38	-0.62	0.37	2.03	1.67	2.78	3.62
FCF Conversion (FCF/Net Income)	1.15x	0.49x	2.13x	0.62x	1.18x	0.43x	0.74x	1.19x	1.38x	1.08x
Interest Paid	0	3.89M	20.3M	16.89M	9.03M	6.53M	3.3M	6.11M	11.41M	10.56M
Taxes Paid	0	1.44M	3.02M	220K	0	0	0	0	31.76M	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-76.42%	-1958.98%	71.6%	-35.14%	-42.41%	106.33%	231.44%	110.23%	222.07%	198.42%
Return on Invested Capital (ROIC)	-51.89%	-74.78%	33.81%	-18.59%	-14.67%	27.93%	30.53%	16.74%	17.42%	25.7%
Gross Margin	78.35%	77.36%	90.16%	93.33%	76.76%	83.79%	81.64%	78.9%	76.8%	84.3%
Net Margin	-23.86%	-70.23%	19.89%	-52.9%	-36.86%	48.24%	90.84%	30.62%	33.96%	43.74%
Debt / Equity	1.16x	-	0.97x	0.51x	4.39x	2.63x	4.45x	8.87x	17.89x	4.14x
Interest Coverage	-5.28x	-4.17x	3.68x	-3.84x	-5.81x	7.08x	36.66x	15.79x	17.99x	30.48x
FCF Conversion	1.15x	0.49x	2.13x	0.62x	1.18x	0.43x	0.74x	1.19x	1.38x	1.08x
Revenue Growth	79.28%	8.61%	115.84%	-52.04%	29.06%	36.53%	65.67%	48.91%	25.62%	22.44%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Royalty	-	-	-	-	69.9M	88.6M	203.9M	360.48M	447.87M	570.99M
Royalty Growth	-	-	-	-	-	26.75%	130.15%	76.79%	24.24%	27.49%
Product	-	-	-	-	66.05M	55.99M	104.22M	191.03M	300.85M	303.49M
Product Growth	-	-	-	-	-	-15.23%	86.16%	83.29%	57.49%	0.88%
Collaborative Agreements	-	-	-	-	60.05M	123.01M	135.19M	108.61M	80.53M	140.84M
Collaborative Agreements Growth	-	-	-	-	-	104.86%	9.90%	-19.66%	-25.85%	74.88%
Bulk rHuPH20	-	-	-	-	-	-	-	-	115.44M	86.33M
Bulk rHuPH20 Growth	-	-	-	-	-	-	-	-	-	-25.21%
Sales-based milestone	-	-	-	-	-	15M	50M	10M	-	30M
Sales-based milestone Growth	-	-	-	-	-	-	233.33%	-80.00%	-	-
Upfront Fees	-	-	-	-	-	-	-	-	-	27M
Upfront Fees Growth	-	-	-	-	-	-	-	-	-	-
Research and Development Services	-	-	-	-	1.54M	1.25M	1.19M	9.61M	9.53M	-
Research and Development Services Growth	-	-	-	-	-	-19.29%	-4.89%	710.37%	-0.80%	-
Upfront fees	-	-	-	-	53M	37.26M	42M	30M	2M	-
Upfront fees Growth	-	-	-	-	-	-29.69%	12.71%	-28.57%	-93.33%	-
bulk rHuPH20	-	-	-	12.73M	48.28M	38.24M	80.96M	82.08M	-	-
bulk rHuPH20 Growth	-	-	-	-	279.33%	-20.81%	111.73%	1.39%	-	-
Development Fees	-	-	-	-	5.5M	69.5M	42M	59M	-	-
Development Fees Growth	-	-	-	-	-	1163.64%	-39.57%	40.48%	-	-
Hylenex Recombinant	-	-	-	-	17M	17.03M	23.26M	-	-	-
Hylenex Recombinant Growth	-	-	-	-	-	0.21%	36.59%	-	-	-
ENHANZE drug product	-	-	-	-	768K	719K	-	-	-	-
ENHANZE drug product Growth	-	-	-	-	-	-6.38%	-	-	-	-
Bulk rHuPH20 for Herceptin SC	22.8M	-	-	-	-	-	-	-	-	-
Bulk rHuPH20 for Herceptin SC Growth	-	-	-	-	-	-	-	-	-	-
Bulk rHuPH20 for HyQvia	6.4M	-	-	-	-	-	-	-	-	-
Bulk rHuPH20 for HyQvia Growth	-	-	-	-	-	-	-	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
SWITZERLAND	57.14M	93.07M	119.14M	109.89M	-	-	-	-	-	-
SWITZERLAND Growth	-	62.89%	28.01%	-7.76%	-	-	-	-	-	-
UNITED STATES	77.15M	52.29M	196.27M	40.48M	-	-	-	-	-	-
UNITED STATES Growth	-	-32.22%	275.34%	-79.38%	-	-	-	-	-	-
Foreign Countries	772K	1.33M	-	-	-	-	-	-	-	-
Foreign Countries Growth	-	72.54%	-	-	-	-	-	-	-	-

Frequently Asked Questions

Valuation & Price

Halozyme Therapeutics, Inc. (HALO) has a price-to-earnings (P/E) ratio of 20.9x. This is roughly in line with market averages.

Growth & Financials

Halozyme Therapeutics, Inc. (HALO) reported $1.24B in revenue for fiscal year 2024. This represents a 2116% increase from $56.1M in 2011.

Halozyme Therapeutics, Inc. (HALO) grew revenue by 22.4% over the past year. This is strong growth.

Yes, Halozyme Therapeutics, Inc. (HALO) is profitable, generating $595.5M in net income for fiscal year 2024 (43.7% net margin).

Dividend & Returns

Halozyme Therapeutics, Inc. (HALO) has a return on equity (ROE) of 198.4%. This is excellent, indicating efficient use of shareholder capital.

Halozyme Therapeutics, Inc. (HALO) generated $602.4M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.